Francois Maisonrouge

Francois Maisonrouge is a Senior Managing Director in Evercore Partners' advisory business with 31 years of relevant experience. At Evercore, Mr. Maisonrouge was involved in advising BTG on its acquisition of Galil, Medivation in its defense across from Sanofi, Shire on its acquisitions of Baxalta and Dyax, Shire in its defense across from Abbvie, and AstraZeneca in its defense across from Pfizer, Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories, Aptalis on its sale to Forest Pharmaceuticals, Bristol-Myers Squibb on its acquisition of Amylin and sale of half of its interest in Amylin to AstraZeneca, Fenwal on its sale to Fresenius, Sage Products on its sale to Madison Dearborn, Terumo on its acquisition of CaridianBCT, Sanofi on its acquisition of Genzyme and of Merck's 50% stake in Merial, Movetis on its sale to Shire, TPG on its acquisition of IMS Health, and Wyeth on its combination with Pfizer. Prior to joining Evercore, Mr. Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology. At Credit Suisse, Mr. Maisonrouge was responsible for leading the firm's relationships with large healthcare clients such as Johnson &a; Johnson, Schering-Plough, Wyeth, GlaxoSmithKline, Roche and Teva, most notably in executing mergers and acquisitions and capital raising transactions. Mr. Maisonrouge has an M.S. in Engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School. He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and the Director of the Pasteur Foundation. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d'honneur